MedPath

Comparison of Postoperative Analgesia Between Intravenous Paracetamol and Intranasal Tapentadol

Phase 4
Completed
Conditions
Lower Limb Fracture
Interventions
Registration Number
NCT05999890
Lead Sponsor
Kempegowda Institute of Medical Sciences, Bangalore
Brief Summary

The aim of the study was to compare the analgesic efficacy of intranasal tapentadol nasal spray 44.5mg and intravenous paracetamol 1gm during the postoperative period by Visual analog scale(VAS)in patients undergoing lower limb(long bone fractures)orthopedic surgeries. Paracetamol is one of the most frequently used analgesic and antipyretic agents, interferes neither with platelet nor kidney functions nor does it present the unwanted side effects of NSAIDs. Tapentadol is a novel, centrally-acting analgesic with a dual mechanism of action, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition. This dual mode of action is responsible for its opioid-sparing effect, which contributes to a reduction in some of the typical opioid-related adverse effects

Detailed Description

Inclusion criteria Age: From 18.00 Year(s) to 60.00 years Gender: Both American Society of Anesthesiologists (ASA) physical status: 1 \& 2, posted for elective lower limb orthopedic surgeries Exclusion criteria

1. Sepsis at the site of injection

2. Coagulopathy

3. Patients with history of renal, hepatic, cardiovascular disease

4. Patient on chronic opioid use Outcome Comparing postoperative analgesia between the groups every 12 hours after the intervention till about 72 hours post intervention. The secondary outcome is to compare the need for the rescue analgesia between the groups

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
74
Inclusion Criteria
  1. American Society of Anesthesiologists (ASA) physical status 1 & 2
  2. Posted for elective lower limb orthopaedic surgeries
Exclusion Criteria
  1. Sepsis at the site of injection
  2. Coagulopathy
  3. Patients with history of renal, hepatic, cardiovascular disease
  4. Patient on chronic opioid use

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TapentadolTapentadol HydrochlorideTapentadol is a novel, centrally acting analgesic with dual mechanism of action, combining mu-opioid receptor agonism with norepinephrine reuptake inhibition.this dual mode of action is responsible for its opioid sparing effect, which contributes to reduction in some of the typical opioid related adverse effects
ParacetamolTapentadol HydrochlorideParacetamol is one of the most frequently used analgesic and antipyretic agent, interferes neither with platelet nor kidney functions nor does it present the unwanted side effects of NSAIDS.
Primary Outcome Measures
NameTimeMethod
Pain as measured with Visual analogue scaleEvery 12 hours after the intervention till about 72 hours after the intervention

The pain rating was done as per a visual analogue scale (VAS) of 0-100 (score 0 = no pain, score 100 - most severe pain). Patients with a VAS score of more than 30, at what is considered as base line, in group A=received IV paracetamol 1gm given every 5-6 hourly and in group B=received intranasal tapentadol 44.5mg nasal spray administered every 5-6 hourly. Patient was assessed for pain by using VAS half an hour after administration and the scores were documented. Pain score were recorded at and after 30 minutes of the intervention in the following time frames - 12hr,24hr,36hr,48hr, 60hr and 72hrs after the baseline intervention (0hr).

Secondary Outcome Measures
NameTimeMethod
The need for rescue analgesiaIn the first 72 hours after the initiation of the intervention

The need for the add on analgesic whenever the subjects request for the same

Trial Locations

Locations (1)

Kempegowda Institute of Medical Sciences

🇮🇳

Bangalore, Karnataka, India

© Copyright 2025. All Rights Reserved by MedPath